Pharmacogenomics News and Research RSS Feed - Pharmacogenomics News and Research

The terms pharmacogenomics and pharmacogenetics are often used interchangeably to describe a field of research focused on how genes affect individual responses to medicines. Whether a medicine works well for you—or whether it causes serious side effects—depends, to a certain extent, on your genes.

Just as genes contribute to whether you will be tall or short, black-haired or blond, your genes also determine how you will respond to medicines. Genes are like recipes—they carry instructions for making protein molecules. As medicines travel through your body, they interact with thousands of proteins. Small differences in the composition or quantities of these molecules can affect how medicines do their jobs.

These differences can be due to diet, level of activity, or the medicines a person takes, but they can also be due to differences in genes. By understanding the genetic basis of drug responses, scientists hope to enable doctors to prescribe the drugs and doses best suited for each individual.
Penn study suggests future precision medicine approach to treating diabetes, other metabolic disorders

Penn study suggests future precision medicine approach to treating diabetes, other metabolic disorders

In the first study of its kind, Penn researchers have shown how an anti-diabetic drug can have variable effects depending on small natural differences in DNA sequence between individuals. Mitchell Lazar, MD, PhD, Raymond Soccio, MD, PhD, and colleagues at the Perelman School of Medicine at the University of Pennsylvania, aim to apply this knowledge to develop personalized approaches to treating diabetes and other metabolic disorders. [More]
DTC genetic testing has negative consequences in children

DTC genetic testing has negative consequences in children

A woman coping with the burden of familial breast cancer can't help but wonder if her young daughter will suffer the same fate. Has she inherited the same disease-causing mutation? Is it best to be prepared for the future, or to wait? During the last decade, genetic tests have been through a sea change, both in their availability and the technologies behind them. Today there are at least 34 companies that offer direct to consumer (DTC) DNA testing, some of which return health results. And now it is possible to sequence someone's entire genetic code for the price of a laptop. [More]
7th Annual Personalized & Precision Medicine Conference to be held in Baltimore from Oct. 5 to 6, 2015

7th Annual Personalized & Precision Medicine Conference to be held in Baltimore from Oct. 5 to 6, 2015

Arrowhead's 7th Annual Personalized & Precision Medicine Conference is coming to Baltimore, MD on October 5-6, 2015 as an official satellite event to the American Society for Human Genetics Annual Meeting. [More]
Future Cardiology’s special issue focuses on recent advances, challenges in cardiology

Future Cardiology’s special issue focuses on recent advances, challenges in cardiology

In recognition of 10 years of publication Future Cardiology has launched a special issue focused on recent advances and emerging challenges in specific areas of cardiology. [More]
Substantial pharmacogenetic information available on cardiovascular drugs

Substantial pharmacogenetic information available on cardiovascular drugs

There is a wealth of published information describing interactions between drugs used to treat cardiovascular disease and the genetic variations that can affect how patients respond to them. But few heart specialists make routine use of this potentially life-saving data. [More]
Study quantifies different mutational profiles of tumour cell clusters in patients with bowel cancer

Study quantifies different mutational profiles of tumour cell clusters in patients with bowel cancer

Bowel cancer is often driven by mutations in one of several different genes, and a patient can have a cancer with a different genetic make-up to another patient's cancer. Identifying the molecular alterations involved in each patient's cancer enables doctors to choose drugs that best target specific alterations. [More]
Agena Bioscience releases LungFUSION Panel to identify gene fusions in NSCLC tumors

Agena Bioscience releases LungFUSION Panel to identify gene fusions in NSCLC tumors

Agena Bioscience today released the LungFUSION Panel for rapid and sensitive identification of oncogenic ALK, RET, and ROS1 gene fusions in non-small cell lung cancer tumors. [More]
UF pharmacy dean to be honored with 2015 SURA Distinguished Scientist Award

UF pharmacy dean to be honored with 2015 SURA Distinguished Scientist Award

SURA today announced that Julie A. Johnson, Dean and Distinguished Professor at the University of Florida's College of Pharmacy, will receive its 2015 SURA Distinguished Scientist Award. [More]
GeneSight test better predicts antidepressant outcomes for patients with depression

GeneSight test better predicts antidepressant outcomes for patients with depression

The combinatorial, multi-gene GeneSight test has been found to better predict antidepressant treatment outcomes for patients with depression, and their use of health care resources, than any of the individual genes that comprise the test, according to a peer-reviewed analysis by investigators from the Mayo Clinic and Assurex Health, and published online by The Pharmacogenomics Journal. [More]
Researchers identify first genetic variation linked to increased risk of peripheral neuropathy

Researchers identify first genetic variation linked to increased risk of peripheral neuropathy

Researchers have identified the first genetic variation that is associated with increased risk and severity of peripheral neuropathy following treatment with a widely used anti-cancer drug. Investigators also found evidence of how it may be possible to protect young leukemia patients without jeopardizing cures. [More]
Agena releases MassARRAY 24-Well System for mass spectrometry-based genetic testing

Agena releases MassARRAY 24-Well System for mass spectrometry-based genetic testing

Agena Bioscience today released the MassARRAY 24-Well System for mass spectrometry-based genetic analysis, adding to its existing MassARRAY portfolio. The new 24-well format is tailored to smaller clinical testing laboratories requiring modest sample throughput, reduced initial hardware costs, and reduced time to result. [More]
Personalized prevention, treatments of cancer now accessible through Stanford University's new genetics course

Personalized prevention, treatments of cancer now accessible through Stanford University's new genetics course

Instrumental research that aims to enhance how we predict, diagnose and design personalized prevention and treatments of cancer is now accessible through Stanford University's latest professional education course, Understanding Cancer at the Genetic Level. [More]
Two genetic mutations can interact to reduce risk for heart attack

Two genetic mutations can interact to reduce risk for heart attack

Researchers have determined that two mutations on a single gene can interact in a way that lowers the carrier's risk for a heart attack. [More]

New initiative aims at reducing adverse effects of medications in individuals with mental illnesses

Geneticists at the University of Pittsburgh Graduate School of Public Health will provide their scientific expertise to a new initiative aimed at preventing and reducing the adverse effects of medications in people with mental illnesses. [More]
Patient's gene profile influences effects of statins

Patient's gene profile influences effects of statins

The Montreal Heart Institute Research Centre is once again pushing the limits of knowledge in personalized medicine. A meta-analysis combining the results of several pharmacogenomic studies and involving over 40,000 research subjects now makes it possible to demonstrate a different response to statins according to the patient's gene profile. [More]
Genome Canada awards $6M grant to CAMH and Assurex Health

Genome Canada awards $6M grant to CAMH and Assurex Health

Assurex Health and Canada's Centre for Addiction and Mental Health (CAMH) today announced they have received a $6 million grant from Genome Canada, an agency of the Canadian government, to study the benefits of genetic testing to guide medication decisions for patients with depression or schizophrenia. [More]
Case Western Reserve researcher lands Director's New Innovator Awards from NIH

Case Western Reserve researcher lands Director's New Innovator Awards from NIH

For the second consecutive year, a Case Western Reserve University School of Medicine researcher has landed one of the year's much-coveted Director's New Innovator Awards from the National Institutes of Health. Principal investigator Rong Xu, PhD, assistant professor of medical informatics, will receive $2,377,000 for five years, starting immediately, to initiate computational analysis of thousands of drugs and their effects. [More]
Gaucher disease: an interview with Dr Clement Olivier, Shire

Gaucher disease: an interview with Dr Clement Olivier, Shire

Gaucher disease is the most common condition within a family of rare diseases known as the lysosomal storage diseases. The disease causes lipids to accumulate in cells, which is why it is referred to as a storage disorder. The accumulation occurs mainly in the spleen, liver, and bones, but may also occur in the lungs, heart, and central nervous system. [More]

Three Scottish universities to offer a new course in stratified medicine

Stratified medicine, which uses the genetic make-up of patients and their differing responses to drugs to create more personalised and effective forms of treatment, has been hailed as one of the most important concepts to emerge in 21st century clinical science. [More]
New avenues for treatment of Alzheimer's disease

New avenues for treatment of Alzheimer's disease

Judes Poirier, PhD, C.Q., from the Douglas Mental Health Institute and McGill University in Montr-al (Canada) and his team have discovered that a relatively frequent genetic variant actually conveys significant protection against the common form of Alzheimer's disease and can delay the onset of the disease by as much as 4 years. [More]
Advertisement